Effects of long-term proBNP cardiac gene delivery in experimental hypertensive heart disease
Year: 2011
Type: article
Abstract: Results In SHR, a single systemic administration of AAV9 vector allowed longterm, cardiac BNP overexpression with an increase in plasma BNP levels as compared with untreated SHR (433.3±17 vs 60.6±15* pg/ml). This further resulted in reductions in systolic (121±11 vs 184 ±13* mm Hg) and diastolic (103±5 vs 148±24* mm Hg) BP for nine months after injection as compared with untreated SHR. Left ventricular (LV) thickness (1.87±0.1 vs 2.16±0.3* mm), LV end-systolic dimensions (3.96±0.3 vs 4.66±0.6* mm) and LV mass (0.4±0.01 vs 0.49±0.01* gr) were reduced, while ejection fraction was increased (83±2 vs 74±4* %) in BNP-treated compared to untreated SHR. Circumferential systolic strain (-5.04±0.4 vs -3.74 ±0.4* %) and strain rate of the early phase of diastole (-4.57±2.1 vs -2.41±1.3 1/s) were improved in BNP-treated compared with controls. Importantly, the improvement in cardiac function and structure also resulted in a significant increase in survival (p<0.001 vs untreated SHR). Non-cardiac overexpression of BNP, via AAV2 vector, was not associated with changes in plasma BNP and BP in SHR. Nevertheless, normotensive Wistar rats injected with AAV9 proBNP vector showed significantly reduced heart/body weights (0.31± 0.1 vs 3.9±0.1* %) four weeks after injection without BP reduction compared to untreated rats.
Source: BMC Pharmacology
Authors: Alessandro Cataliotti, Jason M Tonne, Guido Boerrigter, Salvatore Mangiafico, John C Burnett, Yasuhiro Ikeda
Institution: Mayo Clinic
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W1974931482